Please note: Supplements are generally not FDA tested or approved. Some supplements can interfere with medications including blood pressure meds and anticoagulants. Do not delay seeking medical attention for medical concerns by taking supplements without medical advice. Combining supplements can increase the risk of toxicity and side effects. Statements and product contents have not been independently confirmed by MedicalResearch.com or Eminent Domains Inc. Please discuss any and all supplements you take or are considering taking with your health care provider. Ratings in this post are the opinions of the contributing writer and not MedicalResearch.com or Eminent Domains Inc. GHK-Cu is NOT FDA approved for oral use and is sold for topical use only. Do not use peptides in any form without the express approval of your medical provider. Most injectable or oral peptides are not legally dispensed for non-research purposes.
Copper peptides are gaining traction in skincare and haircare for their ability to revitalize skin and support hair growth. To understand what sets copper peptides apart, it's crucial to examine the scientific research and their growing popularity in beauty routines. A detailed GHK-Cu peptide research guide can help consumers integrate these ingredients more effectively. Designed to work at the cellular level, copper peptides play vital roles in supporting youthful skin and encouraging healthy hair. Exploring the mechanisms behind these compounds offers practical insights for consumers and explains why they are included in many modern formulations.
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Dr. King[/caption]
Brett King, MD, PHD
Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero”
for his work treating patients with severe alopecia areata
Dermatology Physicians of Connecticut
Fairfield, Connecticut
MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata?
Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.